Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 31,373 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose 2 Clear all
Terminated Phase 4 Interventional Results available

A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation

NCT01318811
View directory record Official record
Conditions
Acute Kidney Injury, Acute Renal Failure, Heart Failure
Interventions
Dilute unfractionated heparin, Standard concentration unfractionated heparin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 26, 2026, 9:48 PM EDT
Recruiting Phase 2 Interventional

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

NCT06470971
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Siltuximab
Biological · Procedure · Other
Lead sponsor
Yuanquan Yang
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Not applicable Interventional Results available

Myocardial Stress Perfusion Imaging With Dual Source CT

NCT00853671
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Adenosine Stress Dual-source CTP
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis

NCT02966834
View directory record Official record
Conditions
Cholestasis
Interventions
Placebo, GSK2330672
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Sacramento, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 26, 2026, 9:48 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)

NCT04770064
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
High-dose/short-duration Fisetin, Low-dose/sustained-duration Fisetin, Oral placebo capsule
Drug · Other
Lead sponsor
Austin V Stone
Other
Eligibility
35 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 2 Interventional

A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease

NCT01113593
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Formoterol Fumarate, Foradil Aerolizer
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Clearwater, Florida • DeLand, Florida • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

NCT00551421
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
pertuzumab, cetuximab, irinotecan hydrochloride, immunohistochemistry staining method, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFrEF

NCT04112316
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
Interventions
Liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 26, 2026, 9:48 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

NCT06116916
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
KHK4951, Aflibercept Injection
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
40
States / cities
Mesa, Arizona • Tucson, Arizona • Arcadia, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 26, 2026, 9:48 PM EDT
Terminated Phase 2 Interventional

Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia

NCT00909584
View directory record Official record
Conditions
Severe Chronic Neutropenia
Interventions
Ezatiostat Hydrochloride
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 26, 2026, 9:48 PM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 26, 2026, 9:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

NCT04008784
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
Drug
Lead sponsor
Clinical Research Center of the Carolinas
Other
Eligibility
2 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 26, 2026, 9:48 PM EDT
Terminated Phase 3 Interventional

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

NCT00077233
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, 5-FU, irinotecan, leucovorin, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
77
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04075396
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Duarte, California • Orlando, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 26, 2026, 9:48 PM EDT
Recruiting Phase 4 Interventional

Naltrexone in AUD Reward Drinkers

NCT05028062
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholism
Interventions
XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pain in Fibrous Dysplasia

NCT04125862
View directory record Official record
Conditions
Fibrous Dysplasia/McCune-Albright Syndrome
Interventions
MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT, 18F-NaF-PET/CT
Diagnostic Test
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Interferon as a Mucosal Adjuvant for Influenza Vaccine Given Intranasally

NCT00436046
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza virus vaccine (2006-2007 formulation), Type 1 interferon
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 26, 2026, 9:48 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

NCT01408888
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Sitagliptin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Daytona Beach, Florida • Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 26, 2026, 9:48 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

NCT05548127
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471, Abemaciclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Palo Alto, California • San Francisco, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 1 Interventional

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

NCT00631527
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide, Goserelin, Sunitinib Malate, Casodex, Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 26, 2026, 9:48 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

NCT07654361
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
Aleniglipron, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
3,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 26, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.

NCT04936542
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
AboBoNT-A, OnaBoNT-A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 26, 2026, 9:48 PM EDT